The endothelium-dependent and the endothelium-independent vasodilators in the isolated, perfused guinea pig heart

• Autorzy: Chlopicki S , Gryglewski R.J.
• Języki publikacji: EN

Abstrakty

EN

The endothelium-dependent (acetylcholine, bradykinin, substance P) and the endothelium-independent (gliceryl trinirate, 3-morpholinsydnominine, sodium nitroprusside) vasodilators were studied in the Langendorff-perfused heart of the guinea pig. The involvement of prostanoids and EDRF in the endothelium-dependent responses were assessed by using indomethacin, an inhibitor of cyclooxygenase, and NG -nitro-L-Arginine, an inhibitor of NO synthase. The endothelium-independent agents were used as reference compounds. Both indomethacin and NG -nitro- L-Arginine elevated significantly baseline coronary perfusion pressure, indicating that prostanoids (most likely PGI₂ and PGE₂ ) and EDRF modulate the resting tone of the guinea pig coronary circulation. NG-nitro-L-Arginine, but not indomethacin, considerably reduced receptor-stimulated responses. It is concluded that acetylcholine, bradykinin or substance P-induced vasodilation is mediated by EDRF. In contrast, prostanoids do not contribute to endothelium-dependent responses. In addition, short-term tachyphylaxis to bolus injection of gliceryl trinitrate but not of sodium nitroprusside was demonstrated, suggesting that this preparation may be of value for studying nitrate tolerance.

Słowa kluczowe

EN

coronary microcirculation; tachyphylaxis; prostacyclin; guinea pig; heart; gliceryl trinitrate; endothelium

• Wydawca: -
• Czasopismo: Journal of Physiology and Pharmacology
• Rocznik: 1992
• Tom: 43
• Numer: 4
• Opis fizyczny: p.353-365,fig.

Twórcy

autor

Chlopicki S

• University School of Medicine, 31-531 Krakow, Grzegorzecka 16, Poland

autor

Gryglewski R.J.

Bibliografia

• 1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376.
• 2. Rapoport RM, Murad F. Endothelium-dependent and nitrovasodilator-induced relaxation of vascular smooth muscle: role of cyclic GMP. J Cycl Nuci Prot Phosph Res 1983; 9: 281-296.
• 3. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
• 4. Ignarro LJ, Buga GM, Wood KS, Byrns KS, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265-9269.
• 5. Myers PR, Minor RL, Guerra R, Bates JN, Harrison DG. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. Nature 1990; 345: 161-163.
• 6. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664-666.
• 7. Furchgott RF. The role of endothelium in the responses of vascular smooth muscle to drugs. Ann Rev Pharmacol Toxicol 1984; 24: 175-197.
• 8. Vanhoutte PM, Rubanyi GM, Miller VM, Houston DS. Modulation of vascular smooth muscle contration by the endothelium. Ann Rev Physiol 1986; 48: 307-320.
• 9. Amescua J L, Dusting G J, Palmer R M J, Moncada S. Acetylcholine induce vasodilation in the rabbit isolated heart through the release of nitric oxide, the endogenous nitrovasodilator. Br J Pharmacol 1988; 95: 830-834.
• 10. Amescua J L, Palmer RMJ, de Sousa BM, Moncada S. Nitric oxide synthesized from L-arginine regulates vascular tone in the coronary circulation of the rabbit. Br J Pharmacol 1989; 97: 119-1124.
• 11. Keim M, Schrader J. Nitric oxide release from the isolated guinea pig heart. Eur J Pharmacol 1988; 155-317-321.
• 12. Keim M, Schrader J. Control of vascular tone by nitric oxide. Cir Res 1990; 66: 1561-1575.
• 13. Baydoun AR, Woodward B. Effects of bradykinin in the rat isolated perfused heart: role of kinin receptors and endothelium-derived relaxing factor Br J Pharmacol 1991; 103: 1829-1833.
• 14. Moncada S, Gryglewski RJ, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelets aggregation. Nature 1976; 263: 663-665.
• 15. De Deckere EAM, Nugteren DH, Ten Hoor F. Prostacyclin is the major prostaglandin released from the isolated perfused rabbit and rat heart. Nature 1977; 268: 160-163.
• 16. Schror K, Moncada S, Ubetuba FB, Vane JR. Transformation of arachidonic acid and prostaglandin endoperoxide by the guinea pig heart. Formation of RSC an prostacyclin (PGX). Eur J Pharmacol 1978; 47: 103-114.
• 17. De Nucci G, Gryglewski RJ, Warner T, Vane JR. Receptor-mediated release of endothelium derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci USA 1988; 85: 2334-2338.
• 18. Needleman P, Key SL, Denny SE, Isakson PC, Marshall GR. Mechanism and modification of bradykinin-induced coronary vasodilation. Proc Natl Acad Sci USA 1975; 72: 2060.
• 19. Turker RK, Ercan ZS, Ersoy A, Zengil H. Inhibition by nicotine of the vasodilator effect of bradykinin: evidence for a prostacyclin-dependent mechanism. Arch Int Pharmacodyn 1982; 257: 94.
• 20. Forstermann U, Mugge A, Alheid U, Haverich A, Frolich JC. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Cir Res 1988; 62: 185-190.
• 21. Hintze TH, Kaley G. Prostaglandins and the control of blood flow in the canine myocardium. Cir Res 1977; 40: 313-320.
• 22. Stewart AG, Piper PJ. Vasodilator actions of acetylcholine, A23187 and bradykinin in isolated perfused heart are independent of prostacyclin. Br J Pharmacol 1988; 95: 379-384.
• 23. Lee L, Bruner CA, Webb RC. Prostanoids contribute to endothelium-dependent coronary vasodilation in guinea pig. Blood vessels 1990; 27: 341-351.
• 24. Moore PK, al-Swayek OA, Chong NWS, Evans RA, Gibson A. L-NG-nitro arginine (L-NOARG), a novel, l-arginine reversible inhibitor of endothelium-dependent vasodilation on vitro. Br J Pharmacol 1990; 99: 408-412.
• 25. Ishii K, Chang B, Kerwin JF, Huang ZJ, Murad F. NG-nitro-L-arginine: a potent inhibitor of endothelium-derived relaxing factor formation. Eur J Pharmacol 1990; 176: 219-233.
• 26. Mulsch A, Busse R. NG-nitro-L-arginine (N⁵ [imino-(nitroamino)methyl-]-L-ornithine) impairs endothelium-dependent dilation by inhibiting cytosolic nitric oxide synthesis from L-arginine. Naunyn-Schmiedeberg’s Arch Pharmacol 1990; 341: 143-147.
• 27. Vane JR. Inhibition of prostaglandin biosynthesis as the mechanism of action of aspirin like drugs. Adv Biosci 1973; 9: 395.
• 28. Regoli D, Barabe J. Pharmacology of bradykinin an related kinins. Pharmacol Rev 1980; 32: 1.
• 29. Regoli D, Rhaleb NE, Dion S, Drapeau G. New selective Bk receptor antagonist an bradykinin B2 receptor characterization. TIPS 1990; IT. 156.
• 30. Cowan CL, Cohen RA. Two mechanisms mediate relaxation by bradykinin of pig coronafy artery: NO-dependent and -independent responses. Am J Physiol 1991; 261: H830-835.
• 31. Pelc LR, Gross GJ, Warltier DC. Mechanism of coronary vasodilation produced by bradykinin. Circulation 1990; 83(6): 2048-2056.
• 32. Gardiner SM, Compton AM, Bennett T, Palmer RMJ, Moncada S. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 1990; 15: 486-492.
• 33. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; Oct 28: 997-1000.
• 34. Gerristen ME, Cheli CD. Arachidonic acid and prostaglandin endoperoxide metabolism in isolated rabbit and coronary microvessels and isolated and cultivated coronary microvessel endothelial cells. J Clin Invest 1983; 72: 1658-1671.
• 35. Noll G, Buhler FR, Yang Z, Luscher TF. Different potency of endothelium-dependent relaxing factors against thromboxane, endothelin, and potassium chloride in intramyocardial porcine coronary arteries. J Cardio vase Pharmacol 1991; 18: 120-126.
• 36. Moncada S, Palmer RMJ, Higgs EA. Biosynthesis of nitric oxide from L-arginine: a pathway for the regulation of cell function and communication. Biochem Pharmacol 1989; 38: 1709-1715.
• 37. Trybulec M, Dudek R, Radziszewski W, Swierkosz T, Zembowicz A. Quantification of the potencies of EDRF-releasers from isolated rabbit aortic strips. Acta Physiol Pol 1990: 41: l-4.
• 38. Schror K, Forster S, Woditsch I. On-line measurement of nitric oxide release from organic nitrates in the intact coronary circulation. Naunyn Schmiedebergs Arch Pharmacol 1991; 344(2): 240-246.
• 39. Christie MI, Lewis MJ. A comparison of endothelium-derived relaxing factor activity in the coronary and renal arteries of the pig. Eur J Pharmacol 1991; 202: 143-149.
• 40. Crossman DC, Larkin SW, Fuller RW, Davies GJ, Maseri A. Substance P dilates epicardial coronary arteries and increase coronary blood flow in humans. Cir 1989; 80: 475-484.
• 41. Forstermann U, Warmuth G, Dudel C, Alhied U. Formation and functional importance of endothelium-derived relaxing factor and prostaglandins in the microcirculation. Z Kardiol 1989; Suppl 6: 85-91.
• 42. Ignarro LJ, Lippton H, Edwards JC et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: Evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981; 218: 739-749.
• 43. Fung HJ, Chong S, Kowaluk E. Mechanism of nitrate action an vascular tolerance. EurHeart J 1989; 10(suppl A): 2-6.
• 44. Feelisch M, Kelm M. Biotransformation of organic nitrates to nitric oxide by vascular smooth muscle and endothelial cells. Biochem Biophys Res Commun 1991; 180: 286- 293.
• 45. Schror K, Forster S, Woditsch I, Schroder H. Generation of NO from molsidomine (SIN-1) in vitro an its relationship to changes in coronary vessel tone. J Cardiovasc Pharmacol 1989; 14(Suppl 11): 29-34.
• 46. Gryglewski RJ, Zembowicz A, Salvemini D, Taylor GW, Vane JR. Modulation of the pharmacological actions of nitrovasodilators by methylene blue and pyocyanin. Br J Pharmacol 1992; 196: 838-845.
• 47. Needleman P, Jakschik B, Johnson EM. Sulfhydryl requirement for relaxation of vascular smooth muscle. J Pharmacol Exper Ther 1973; 187: 324-331.
• 48. Needleman P, Jonson EM. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther 1973; 184: 709-715
• 49. Axelsson KL, Karlsson JO. Nitroglycerin tolerance in vitro: effect on cGMP turnover in vascular smooth muscle. Acta Pharmacol Toxicol Copenh 1984; 55: 203-210.
• 50. Forster S, Woditsch I, Schroder H, Schror H. Reduced nitric oxide release causes nitrate tolerance in the intact coronary circulation. J Cardiovasc Pharmacol 1991; 17: 867-872.
• 51. Boesgaard S, Petersen JS, Aldershvile J, Poulsen HE, Flachs H. Nitrate tolerance: effect of thiol supplementation during prolonged nitroglycerin infusion in an in vivo rat model. J Pharmacl Exp Ther 1991; 258: 851-856.
• 52. Parker JO, Farrel B, Lahey KA, Rose BF. Nitrate tolerance: The lack of effect of N-acetylcysteine. Circulation 1987; 76: 572-576.
• 53. Munzel T, Holtz J, Mulsch A, Stewart DJ, Bessenge E. Failure of the sulfhydryl donor N-acetylcysteine (NAC) to reverse nitrate tolerance in large epicardial arteries and the venous capacitance system of the dog. Z Kariol 1989; 78 (Suppl 2): 26-8.
• 54. Holtz J, Munzel T, Stewart DJ, Bessenge E. Nitrate action on epicardial coronary arteries an tolerance: new aspects based on long term glyceryl trinitrate infusion in dogs. Eur Heart J 1989; 10 (Suppl F): 127-133.
• 55. Dupuis J, Lalonde G, Lemieux R, Rouleau JL. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation an lack of prevention with N-acetylcysteine. J Am Coll Cardiol 1990; 16: 923-931.